IIT Jodhpur researchers develop nanosensor for detection of cytokines

Written By :  Kajal Rajput
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-09 08:30 GMT   |   Update On 2024-04-09 08:45 GMT

Jodhpur: Researchers from the Indian Institute of Technology, Jodhpur, have unveiled a nanosensor designed to swiftly detect cytokines, a group of proteins pivotal in regulating various cells within the body."This development aims to reduce the mortality rate occurring due to delayed diagnosis and a lack of early warnings. Moreover, the technology has immense potential to be used as a rapid...

Login or Register to read the full article

Jodhpur: Researchers from the Indian Institute of Technology, Jodhpur, have unveiled a nanosensor designed to swiftly detect cytokines, a group of proteins pivotal in regulating various cells within the body.

"This development aims to reduce the mortality rate occurring due to delayed diagnosis and a lack of early warnings. Moreover, the technology has immense potential to be used as a rapid and point-of-care technique for health monitoring, disease diagnosis, prognosis, and immune response tracking," reads statement from IIT Jodhpur.

Cytokines, among the numerous biomarkers of inflammation, serve as crucial indicators for diagnosing diseases and monitoring their progression.

Also Read:Hospitalisation cost in private several times greater than public hospitals, says IIT Jodhpur study

According to a PTI report, "Cytokines play an important role in tissue damage repair, cancer development and progression, and modulating immune reactions. This is why they are important for developing precision medicine and targeted therapeutics for various conditions like oncology, infectiology and in rheumatological diseases, among others," the statement added. 

Prof Ajay Agarwal, Department of Electrical Engineering, IIT Jodhpur, said the technique has provided exciting results. 

"This technique which is currently in its development stage has provided exciting and encouraging results for three biomarkers i.e. interleukin-6 (IL-6), interleukin-b (IL-b), and TNF-a which are key pro-inflammatory cytokines, released by inflammatory cells. As of now, the testing is done for controlled samples, but the team aims to take the technology to clinical trials soon. The group is also using this technique, to develop detection protocols for the early-stage and quick diagnosis of Sepsis and Fungal infections," he said.

This novel sensor developed at the IIT uses Surface Enhanced Raman Spectroscopy to detect analytes even at low concentrations. It is based on semiconductor process technology and works on the principle of Surface Enhanced Raman Scattering (SERS).

Hence, it makes this technique powerful and capable of detecting trace-level molecules with high precision and selectivity.

Currently, the most prevalent techniques for cytokine detection include enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). Despite their reliability, these methods are highly time-consuming and necessitate trained personnel, with sample preparation or analysis durations exceeding 6 hours. In contrast, the sensor developed by IIT Jodhpur delivers results within just 30 minutes, rendering it not only efficient but also cost-effective.

Furthermore, this sensor, serving as a rapid and selective diagnostic tool, is complemented by AI for swift and accurate data processing and analysis.

By facilitating faster and more robust diagnoses of autoimmune diseases and bacterial infections, this sensor holds the potential to revolutionize patients' medical treatments. Prompt diagnosis and tracking of diseases can guide the future course of treatment, thereby enhancing patient care and outcomes.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News